Form 4: Beam Therapeutics Chief Legal Officer Receives 20,000 Restricted Stock Units

Christine Bellon, Chief Legal Officer of Beam Therapeutics, was granted 20,000 restricted stock units (RSUs) on March 31, 2025, under the company's 2019 Equity Incentive Plan.

Summary

• Christine Bellon, the Chief Legal Officer of Beam Therapeutics Inc., received 20,000 restricted stock units (RSUs) on March 31, 2025.
• The RSUs were granted under the Beam Therapeutics Inc. 2019 Equity Incentive Plan.
• Each RSU represents the contingent right to receive one share of Beam Therapeutics' common stock.
• The RSUs vest in four substantially equal installments on each of the first four anniversaries of the grant date, contingent upon Ms. Bellon's continued service with Beam Therapeutics.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation matter, which is generally neutral to positive as it incentivizes key personnel. The sentiment is moderately positive.

Positives

• The grant of RSUs aligns the Chief Legal Officer's interests with those of the shareholders, incentivizing her to contribute to the company's long-term success.
• The vesting schedule encourages continued service and commitment to Beam Therapeutics.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract and retain key personnel. Grants of RSUs are a typical component of executive compensation packages.

Comparison to Industry Standards

• Equity compensation packages for Chief Legal Officers in biotech companies of similar size to Beam Therapeutics typically include a mix of stock options and restricted stock units.
• The size of the RSU grant is likely determined based on factors such as the executive's experience, performance, and the company's overall compensation strategy.

Stakeholder Impact

• Shareholders may view the RSU grant as a positive sign, indicating the company's commitment to retaining key executives.
• Employees may see the grant as a reflection of the company's overall compensation philosophy.

Key Dates

Keywords

Beam Therapeutics, Restricted Stock Units, RSUs, Equity Incentive Plan, Beneficial Ownership, Form 4, Christine Bellon, Chief Legal Officer